GAINESVILLE, Fla.--(BUSINESS WIRE)--May 9, 2008 - Exactech Inc., a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that it has entered into definitive agreements with certain institutional investors to sell 877,391 shares of its common stock.

EWING, NJ -- May 9, 2008 -- DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company"), a late-stage biopharmaceutical company, announced today that its President and Chief Executive Officer Christopher J. Schaber, PhD, has joined the Board of Directors of the Alliance for Biosecurity, a collaboration among leading biosecurity research organizations and select biopharmaceutical companies committed to developing biodefense countermeasures to address a range of bioterrorism and natural pandemic threats.

WEST CONSHOHOCKEN, Pa., May 09, 2008 /PRNewswire/ -- Cadient Group, the premier strategic interactive marketing agency serving the healthcare industry, announced today it received two gold and one silver Aster Awards -- which recognize the nation's most talented healthcare marketing professionals for outstanding excellence in advertising. The Aster Awards are a medical marketing awards program that allows healthcare organizations and advertising agencies to compete against similarly-sized competitors, both nationally and worldwide.

BETHESDA, Md., May 09, 2008 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. , today announced that Al Rajhi Holdings W.L.L. ("Al Rajhi") has entered into an agreement, executed on May 6 2008, to provide NWBT with debt financing in the amount of US$4.0 million (the "Loan").

NUTLEY, N.J., May 09, 2008 /PRNewswire/ -- Roche today announced one-year results from a new two-year Phase III study showing that Actemra (tocilizumab) can significantly inhibit progression of structural damage to joints in patients with rheumatoid arthritis, a critical measure of effectiveness of an RA treatment.

DUBLIN, Ireland--(BUSINESS WIRE)--May 9, 2008 - Research and Markets (http://www.researchandmarkets.com/reports/c91235) has announced the addition of Frost & Sullivan's new report: Life Sciences Funding in Europe (2007) to their offering.

DOYLESTOWN, Pennsylvania and OXFORD, England, May 09, 2008 /PRNewswire/ -- EUSA Pharma Inc, a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced that it has completed its acquisition of Cytogen Corporation, following the approval of Cytogen's shareholders at a special meeting on 8 May.

NEW YORK--(BUSINESS WIRE)--May 9, 2008 - Omrix Biopharmaceuticals, Inc. ("Omrix" or the "Company") (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, today announced financial results for the first quarter ended March 31, 2008:

SOUTHFIELD, Mich., May 09, 2008 /PRNewswire/ -- Dr. Michael W. Long recently was named the third-annual Grant Thornton Leader and Innovator of the Year. The "Leader & Innovator" award recognizes and rewards leaders and innovators in the state of Michigan who have demonstrated or created unique ideas, products or abilities that generate a better quality of life in our communities. Nominees were recognized this month at a ceremony at for their proven, successful leadership of Michigan companies, community organizations and enterprises.

ST. DAVID'S, Bermuda, May 09, 2008 /PRNewswire-FirstCall/ -- Warner Chilcott Limited today announced its results for the quarter ended March 31, 2008. Revenue in the quarter ended March 31, 2008 totaled $229.5 million, an increase of 5.1%, over the prior year quarter.